Seeking evaluation at a community health clinic, a 32-year-old woman (G2P2) reports a 3-da… — USMLE Step 2 CK

Seeking evaluation at a community health clinic, a $32$ -year-old woman (G2P2) reports a $3$ -day history of continuous, dull bilateral lower abdominal pain accompanied by new-onset malodorous vaginal discharge. She states she has been in a new monogamous sexual relationship for the past $2$ months. Her medical history is unremarkable, and she uses a copper intrauterine device (IUD) that was placed $3$ years ago for contraception. Vital signs show a blood pressure of $118/76\text{ mmHg}$ , a pulse of $88\text{/min}$ , and a temperature of $37.7^\circ\text{C}$ ( $99.9^\circ\text{F}$ ). Speculum examination reveals a normal-appearing cervix with visible IUD strings and thick, yellowish-green mucopurulent discharge at the cervical os. Bimanual examination elicits significant cervical motion tenderness as well as bilateral adnexal tenderness without palpable masses. A urine pregnancy test is negative. Pelvic ultrasound confirms the IUD is appropriately positioned within the endometrial cavity and demonstrates normal-appearing ovaries with no complex fluid collections or tubo-ovarian abscesses. The patient tolerates oral fluids without difficulty. Which of the following is the most appropriate next step in management?

A
Intramuscular ceftriaxone, oral doxycycline, and oral metronidazole; remove the intrauterine device immediately
Intramuscular ceftriaxone, oral doxycycline, and oral metronidazole; leave the intrauterine device in placeAnswer
C
Intramuscular ceftriaxone and oral azithromycin; leave the intrauterine device in place
D
Admit to the hospital for intravenous cefotetan and intravenous doxycycline; leave the intrauterine device in place
E
Intramuscular ceftriaxone and oral doxycycline; leave the intrauterine device in place

Answer

The most appropriate next step in management is to administer intramuscular ceftriaxone, oral doxycycline, and oral metronidazole, and to leave the intrauterine device in place.

This patient presents with mild-to-moderate pelvic inflammatory disease (PID). According to current clinical guidelines, the recommended outpatient treatment for PID consists of a single dose of intramuscular ceftriaxone combined with a 14-day course of both oral doxycycline and oral metronidazole. Metronidazole is now a mandatory component of this regimen to provide essential anaerobic coverage, which has been shown to improve overall clinical outcomes and decrease the risk of reproductive sequelae. Furthermore, for patients who develop PID while using an intrauterine device (IUD), the standard of care is to leave the device in place, initiate empiric antibiotic therapy, and reassess the patient's clinical response in 48 to 72 hours. Removal is only indicated if the patient fails to improve with appropriate medical therapy.

Step-by-Step Solution

Evaluate the clinical presentation and physical examination findings.

The patient is diagnosed with Pelvic Inflammatory Disease (PID) based on the classic triad of cervical motion tenderness, adnexal tenderness, and purulent cervical discharge.

Recognizing the diagnostic criteria for PID is the required first step before initiating empiric therapy.

Determine the severity of the illness to triage the appropriate care setting (inpatient vs. outpatient).

Outpatient management is indicated.

The patient is hemodynamically stable, has a low-grade temperature rather than a high fever, is not pregnant, tolerates oral intake, and lacks evidence of a tubo-ovarian abscess on ultrasound.

Select the correct pharmacotherapy regimen based on updated treatment guidelines.

A regimen of intramuscular ceftriaxone, oral doxycycline, and oral metronidazole is selected.

Current CDC guidelines require the addition of metronidazole to all standard outpatient PID regimens to provide robust anaerobic coverage, which improves outcomes and reduces complication risks.

Determine the proper management of the patient's intrauterine device (IUD).

The IUD is left in place.

Evidence shows that outcomes for PID are similar whether the IUD is removed or left in place. Guidelines recommend initiating antibiotics with the IUD in situ and considering removal only if there is no clinical improvement after 48 to 72 hours.

Key Concept

Outpatient treatment of uncomplicated pelvic inflammatory disease requires a regimen of intramuscular ceftriaxone, oral doxycycline, and oral metronidazole; concurrent intrauterine devices should be left in place with reassessment at 48 to 72 hours.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic